Talking General Practice BONUS EPISODE: Understanding genetic kidney risk in South Asian populations - sponsored by Alnylam Pharmaceuticals
In this special bonus episode Talking General Practice speaks to consultant nephrologist Dr Shafi Malik about the heightened risk of genetic kidney conditions among South Asian populations.
In this conversation, Dr Malik explains why patients of South Asian origin are more at risk of genetic kidney disease and how common these conditions are. He talks specifically about primary hyperoxaluria type 1 (PH1), the symptoms patients might present with if they have this condition - including recurrent kidney stones - and, as kidney stones are a common presentation, how healthcare professionals can recognise when these cases may warrant further investigation.
This episode was presented by GPonline editor Emma Bower. It was produced by Czarina Deen.
This episode of Talking General Practice has been funded by Alnylam Pharmaceuticals and produced in collaboration with GPonline. It is intended for UK healthcare professionals only.
Useful links
National Kidney Federation – PH1
About Alnylam Pharmaceuticals
Alnylam is a leading biopharmaceutical company and the pioneer in RNA interference (RNAi), a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam has translated the Nobel Prize-winning science of RNAi into an innovative class of medicines, with the belief that the RNAi approach to treating disease has the potential to help people around the world live longer, healthier and more fulfilling lives.
Hosted on Acast. See acast.com/privacy for more information.